Evidence map›Paper›PMID 35869803›Full record

ArticleMycoses2022

Molecular epidemiology and clinical-laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil.

Armando Guevara, Andréia Ferreira Nery, Márcia de Souza Carvalho Melhem, Lucas Bonfietti, Anderson Messias Rodrigues, Ferry Hagen, Jamile Ambrósio de Carvalho, Zoilo Pires de Camargo, Bruna Jacomel F de Souza Lima, Vânia Aparecida Vicente and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Mycoses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Chromoblastomycosis in Brazil: A review of 450 published cases.Revista da Sociedade Brasileira de Medicina Tropical · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Armando GuevaraLaboratory of Mycology/Research, Faculty of Medicine, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil.
Andréia Ferreira NeryJúlio Muller University Hospital, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil.
Márcia de Souza Carvalho MelhemHealth Department, Mycology Nucleus of Instituto Adolfo Lutz, São Paulo, SP, Brazil.
Lucas BonfiettiHealth Department, Mycology Nucleus of Instituto Adolfo Lutz, São Paulo, SP, Brazil.
Anderson Messias RodriguesLaboratory of Emerging Fungal Pathogens, Department of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.ORCID https://orcid.org/0000-0003-0891-4563
Ferry HagenWesterdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-5622-1916
Jamile Ambrósio de CarvalhoLaboratory of Emerging Fungal Pathogens, Department of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Zoilo Pires de CamargoLaboratory of Emerging Fungal Pathogens, Department of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Bruna Jacomel F de Souza LimaMicrobiology, Parasitology and Pathology Post-Graduation Program, Department of Pathology, Federal University of Paraná, Curitiba, Paraná, Brazil.
Vânia Aparecida VicenteDepartment of Medical Microbiology, Utrecht University Medical Center, Utrecht, The Netherlands.
Rosane Christine HahnLaboratory of Mycology/Research, Faculty of Medicine, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil.ORCID https://orcid.org/0000-0003-2686-8193
Universidade Federal de Mato Grosso · BRUniversidade Federal de São Paulo · BRUtrecht University · NLInstituto Adolfo Lutz · BRUniversidade Federal de Mato Grosso do Sul · BRUniversidade Federal do Paraná · BR

Funding

National Council for Scientific and Technological Development 304902/2020-9National Council for Scientific and Technological Development 433276/2018-5São Paulo Research Foundation 2017/27265-5São Paulo Research Foundation 2018/24304-2
6 · The paper itself

Abstract

introductionChromoblastomycosis is a disease caused by melanized fungi, primarily belonging to the genera Fonsecaea and Cladophialophora, mainly affecting individuals who are occupationally exposed to soil and plant products. This research aimed to determine the clinical, epidemiological and laboratory characteristics of chromoblastomycosis in the state of Mato Grosso, Brazil. MATERIALS AND

methodsPatients diagnosed with chromoblastomycosis treated at the Júlio Müller University Hospital, Cuiabá, Brazil, from January 2015 to December 2020, whose isolates were preserved in the Research Laboratory of the Faculty of Medicine of the Federal University of Mato Grosso. Isolates were identified by partly sequencing the Internal Transcribed Spacer (ITS) and β-tubulin (BT2) loci. AFLP fingerprinting was used to explore the genetic diversity. Susceptibility to itraconazole, voriconazole, 5-fluorocytosine, terbinafine and amphotericin B was determined by the broth microdilution technique.

resultsTen patients were included, nine were male (mean age = 64.1 years). Mean disease duration was 8.6 years. Lesions were mainly observed in the lower limbs. Predominant clinical forms were verrucous and scarring. Systemic arterial hypertension and type II diabetes mellitus were the predominant comorbidities. Leprosy was the main concomitant infectious disease. Fonsecaea pedrosoi was the unique aetiological agent identified with moderate genetic diversity (H = 0.3934-0.4527; PIC = 0.3160-0.3502). Antifungal agents with the highest activity were terbinafine, voriconazole and itraconazole.

conclusionChromoblastomycosis is affecting the poor population in rural and urban areas, mainly related to agricultural activities, with F. pedrosoi being the dominant aetiologic agent. All isolates had low MICs for itraconazole, voriconazole and terbinafine, confirming their importance as therapeutic alternatives for chromoblastomycosis.

Indexed as

ChromoblastomycosisDiabetes Mellitus, Type 2Amplified Fragment Length Polymorphism AnalysisAntifungal AgentsBrazilHumansItraconazoleMiddle AgedMolecular EpidemiologyTerbinafineVoriconazoleAntifungal AgentsItraconazoleTerbinafineVoriconazoleAFLPchromoblastomycosischromomycosisepidemiologyFonsecaea pedrosoimolecular epidemiology

Identifiers

PMID35869803
PMCPMC9828117
OpenAlexW4286697204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.